JP2017535564A - Ｐａｒｐ阻害剤の結晶形態 - Google Patents

Ｐａｒｐ阻害剤の結晶形態 Download PDF

Info

Publication number
JP2017535564A
JP2017535564A JP2017527299A JP2017527299A JP2017535564A JP 2017535564 A JP2017535564 A JP 2017535564A JP 2017527299 A JP2017527299 A JP 2017527299A JP 2017527299 A JP2017527299 A JP 2017527299A JP 2017535564 A JP2017535564 A JP 2017535564A
Authority
JP
Japan
Prior art keywords
compound
crystalline form
form according
further characterized
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017527299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017535564A5 (OSRAM
Inventor
ジェイ． ビエルマイヤー、スティーブン
ジェイ． ビエルマイヤー、スティーブン
シー． ハルティヴァンガー、ラルフ
シー． ハルティヴァンガー、ラルフ
ジェイ． ジェイコブス、マーティン
ジェイ． ジェイコブス、マーティン
Original Assignee
セファロン、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セファロン、インク． filed Critical セファロン、インク．
Publication of JP2017535564A publication Critical patent/JP2017535564A/ja
Publication of JP2017535564A5 publication Critical patent/JP2017535564A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
    • C07C59/06—Glycolic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2017527299A 2014-11-26 2015-11-25 Ｐａｒｐ阻害剤の結晶形態 Pending JP2017535564A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462084652P 2014-11-26 2014-11-26
US62/084,652 2014-11-26
PCT/US2015/062572 WO2016086080A1 (en) 2014-11-26 2015-11-25 Crystalline forms of parp inhibitors

Publications (2)

Publication Number Publication Date
JP2017535564A true JP2017535564A (ja) 2017-11-30
JP2017535564A5 JP2017535564A5 (OSRAM) 2018-12-27

Family

ID=54849709

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017527299A Pending JP2017535564A (ja) 2014-11-26 2015-11-25 Ｐａｒｐ阻害剤の結晶形態

Country Status (13)

Country Link
US (1) US10150772B2 (OSRAM)
EP (1) EP3224259A1 (OSRAM)
JP (1) JP2017535564A (OSRAM)
KR (1) KR20170088894A (OSRAM)
CN (1) CN107207511A (OSRAM)
AU (1) AU2015353549A1 (OSRAM)
BR (1) BR112017010588A2 (OSRAM)
CA (1) CA2967828A1 (OSRAM)
HK (1) HK1244006A1 (OSRAM)
IL (1) IL252162A0 (OSRAM)
MX (1) MX2017006679A (OSRAM)
RU (1) RU2017120655A (OSRAM)
WO (1) WO2016086080A1 (OSRAM)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541322A (ja) * 2006-06-19 2009-11-26 セファロン、インク． 新規多環式化合物およびその使用
JP2010510312A (ja) * 2006-11-20 2010-04-02 セファロン、インク． 放射線増感剤を用いた放射線感受性腫瘍に対する方法
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122679B2 (en) 2000-05-09 2006-10-17 Cephalon, Inc. Multicyclic compounds and the use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009541322A (ja) * 2006-06-19 2009-11-26 セファロン、インク． 新規多環式化合物およびその使用
JP2010510312A (ja) * 2006-11-20 2010-04-02 セファロン、インク． 放射線増感剤を用いた放射線感受性腫瘍に対する方法
JP2013503173A (ja) * 2009-08-26 2013-01-31 セファロン、インク． 多環系化合物の新規形態

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
第十六改正 日本薬局方, JPN6014035187, 2011, pages 64 - 68, ISSN: 0004223464 *

Also Published As

Publication number Publication date
IL252162A0 (en) 2017-07-31
BR112017010588A2 (pt) 2018-05-15
US10150772B2 (en) 2018-12-11
RU2017120655A3 (OSRAM) 2018-12-14
CN107207511A (zh) 2017-09-26
KR20170088894A (ko) 2017-08-02
WO2016086080A1 (en) 2016-06-02
CA2967828A1 (en) 2016-06-02
AU2015353549A1 (en) 2017-06-01
EP3224259A1 (en) 2017-10-04
RU2017120655A (ru) 2018-12-14
US20170267683A1 (en) 2017-09-21
MX2017006679A (es) 2018-07-06
HK1244006A1 (zh) 2018-07-27

Similar Documents

Publication Publication Date Title
JP6328737B2 (ja) Ｌ−オルニチンフェニルアセテートおよびその製造方法
KR102845326B1 (ko) Gabaa 양성 알로스테릭 조절인자의 염 및 결정 형태
US10370406B2 (en) Salts and polymorphs of SCY-078
EP3239138A1 (en) Hydrogen fumarate salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]piperidine
EA025561B1 (ru) Твёрдые формы производного хиназолина и их применение в качестве ингибитора braf
EA028351B1 (ru) Твердые формы гидрохлорида вемурафениба
CA3108007C (en) Highly stable crystalline eltrombopag monoethanolamine salt form d1
US20240116925A1 (en) Salt of nitrogen-containing fused heterocyclic compound or crystal form thereof, and preparation method therefor, pharmaceutical composition thereof, and use thereof
US10150772B2 (en) Crystalline forms of PARP inhibitors
WO2019080865A1 (zh) 一种炔基吡啶类脯氨酰羟化酶抑制剂的晶型及其制备方法
EP2922838B1 (en) Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
TW202035388A (zh) Lta4h抑制劑的晶型
Mortko et al. Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation development
KR20260066052A (ko) 베주클라스티닙의 결정형, 이의 제조방법 및 이의 용도
HK40079381A (en) Novel salts and polymorphs of scy-078
CN116375624A (zh) 吡咯烷类化合物的盐及其用途
WO2016113242A1 (en) Di-pidotimod benzathine and solid forms thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181114

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190725

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200303